glp-1 medications market comparison Drugs Size to Hit USD 132.79 Bn by 2035 GLP 1 Drug Biosimilar Market

For instance, New Zealand guidelines recommend offering GLP1RAs to all patients with HbA1c levels above target, especially when GLP1RA use would provide additional reductions in cardiovascular risk and/or permit reduction or cessation of other therapies that contribute to weight gain or hypoglycemia

Gastroenterology 1989

In the PIONEER- 4 trial, semaglutide was not less effective than liraglutide at lowering HbA1c at its daily oral formulation dose [97]

Tsai TH, Sun CK, Su CH, Sung PH, Chua S, Zhen YY

Many patients scale up gradually as their body adapts, spreading costs across several months

35 Biguanides: Metformin reduces the FPG and A1C and has been proven to be safe by trial evidence, showing only mild gastrointestinal (GI) effects and no serious adverse effects